Previous Study: TRIO023
Next Study: TRIO020

Studies & Results


A Randomized, multicenter, open-label, two-arm, Phase III neo-adjuvant study evaluating trastuzumab emtansine plus pertuzumab compared with chemotherapy plus trastuzumab emtansine and pertuzumab for patients with HER2-positive breast cancer

View FDA Study View EU Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at